COVID-19 UPDATE

Contact

BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

Financials & Filings

Filing date	Description	Form	Filing Group	Issuer	View
Aug 11, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000121.pdf 0001103021-20-000121.rtf 0001103021-20-000121.xls
Aug 11, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000123.pdf 0001103021-20-000123.rtf 0001103021-20-000123.xls
Aug 11, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000125.pdf 0001103021-20-000125.rtf 0001103021-20-000125.xls
Aug 11, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000127.pdf 0001103021-20-000127.rtf 0001103021-20-000127.xls
Aug 11, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000129.pdf 0001103021-20-000129.rtf 0001103021-20-000129.xls
Aug 11, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000132.pdf 0001103021-20-000132.rtf 0001103021-20-000132.xls
Aug 11, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000134.pdf 0001103021-20-000134.rtf 0001103021-20-000134.xls
Aug 05, 2020	Report of unscheduled material events or corporate event	8-K	Current Reports	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000116.pdf 0001103021-20-000116.rtf 0001103021-20-000116.xls
Aug 05, 2020	Quarterly report which provides a continuing view of a company's financial position	10-Q	Quarterly Filings	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000119.pdf 0001103021-20-000119.rtf 0001103021-20-000119.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Aug 03, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-20-000107.pdf 0001103021-20-000107.rtf 0001103021-20-000107.xls

Data provided by Kaleidoscope.

Recent BDSI News

BioDelivery Sciences Reports Second Quarter 2021 Results August 4, 2021

Total Company Net Revenue of $41.4 Million Driven by BELBUCA ® All-Time High TRx Market Share Strong Profitability with GAAP Net Income of $9.1 Million , or $0.09 per share, EBITDA Margin of 32%, and Non-GAAP Net Income of $12.5 Million , or $0.12 per Share, Drives Operating Cash Generation of $9.2 ...

BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved ELYXYB™ for the Acute Treatment of Migraine August 4, 2021

The only FDA-approved, ready-to-use oral solution for the acute treatment of migraine with or without aura in adults First step to building a growth platform in Neurology Patent protection until 2036 RALEIGH, N.C. , Aug. 04, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , ...

BioDelivery Sciences to Report Second Quarter 2021 Financial Results on August 4, 2021 July 22, 2021

RALEIGH, N.C. , July 22, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its second quarter 2021 ...

More news

More events

Stay Connected

Stay up to date on the latest news

Get started now